157 related articles for article (PubMed ID: 10353742)
1. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma.
Møller MB; Gerdes AM; Skjødt K; Mortensen LS; Pedersen NT
Clin Cancer Res; 1999 May; 5(5):1085-91. PubMed ID: 10353742
[TBL] [Abstract][Full Text] [Related]
2. Expression of p53 protein in T- and natural killer-cell lymphomas is associated with some clinicopathologic entities but rarely related to p53 mutations.
Petit B; Leroy K; Kanavaros P; Boulland ML; Druet-Cabanac M; Haioun C; Bordessoule D; Gaulard P
Hum Pathol; 2001 Feb; 32(2):196-204. PubMed ID: 11230707
[TBL] [Abstract][Full Text] [Related]
3. Cyclin D3 expression in non-Hodgkin lymphoma. Correlation with other cell cycle regulators and clinical features.
Møller MB; Nielsen O; Pedersen NT
Am J Clin Pathol; 2001 Mar; 115(3):404-12. PubMed ID: 11242797
[TBL] [Abstract][Full Text] [Related]
4. Molecular control of the cell cycle in cancer: biological and clinical aspects.
Møller MB
Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
[TBL] [Abstract][Full Text] [Related]
5. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.
Ichikawa A; Kinoshita T; Watanabe T; Kato H; Nagai H; Tsushita K; Saito H; Hotta T
N Engl J Med; 1997 Aug; 337(8):529-34. PubMed ID: 9262496
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of three subtypes of primary sinonasal lymphoma characterized by immunophenotypic analysis.
Kim GE; Koom WS; Yang WI; Lee SW; Keum KC; Lee CG; Suh CO; Hahn JS; Roh JK; Kim JH
Head Neck; 2004 Jul; 26(7):584-93. PubMed ID: 15229900
[TBL] [Abstract][Full Text] [Related]
7. Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas.
Paik JH; Jeon YK; Park SS; Kim YA; Kim JE; Huh J; Lee SS; Kim WH; Kim CW
Histopathology; 2005 Sep; 47(3):281-91. PubMed ID: 16115229
[TBL] [Abstract][Full Text] [Related]
8. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers.
Migaldi M; Sgambato A; Garagnani L; Ardito R; Ferrari P; De Gaetani C; Cittadini A; Trentini GP
Clin Cancer Res; 2000 Aug; 6(8):3131-8. PubMed ID: 10955794
[TBL] [Abstract][Full Text] [Related]
9. Influence of p53 mutation on pathological grade, but not prognosis of non-Hodgkin's lymphoma.
Osada M; Ishioka C; Ichinohasama R; Kadowaki I; Murakawa Y; Watanabe M; Kanamaru R; Ikawa S
Anticancer Drug Des; 1999 Apr; 14(2):107-14. PubMed ID: 10405637
[TBL] [Abstract][Full Text] [Related]
10. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
11. The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma.
Visco C; Canal F; Parolini C; Andreoli A; Ambrosetti A; Krampera M; Lestani M; Pizzolo G; Chilosi M
Haematologica; 2006 May; 91(5):687-90. PubMed ID: 16670073
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
13. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
[TBL] [Abstract][Full Text] [Related]
14. p53, p21 and p27 protein expression in head and neck cancer and their prognostic value.
Kapranos N; Stathopoulos GP; Manolopoulos L; Kokka E; Papadimitriou C; Bibas A; Yiotakis J; Adamopoulos G
Anticancer Res; 2001; 21(1B):521-8. PubMed ID: 11299798
[TBL] [Abstract][Full Text] [Related]
15. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
16. Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients.
Goan YG; Hsu HK; Chang HC; Chou YP; Chiang KH; Cheng JT
Ann Thorac Surg; 2005 Sep; 80(3):1007-16. PubMed ID: 16122475
[TBL] [Abstract][Full Text] [Related]
17. Loss of p21 expression is associated with p53 mutations and increased cell proliferation and p27 expression is associated with apoptosis in maxillary sinus squamous cell carcinoma.
Bandoh N; Hayashi T; Takahara M; Kishibe K; Ogino T; Katayama A; Imada M; Nonaka S; Harabuchi Y
Acta Otolaryngol; 2005 Jul; 125(7):779-85. PubMed ID: 16012042
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotype, histopathology and clinical stage: their predictive value in the prognosis of non-Hodgkin's lymphomas.
Mtasiwa DM; Imamura N; Inada T; Takimoto Y; Okada K; Nanba K; Asaoku H; Kuramoto A
Hiroshima J Med Sci; 1990 Dec; 39(4):95-102. PubMed ID: 2086567
[TBL] [Abstract][Full Text] [Related]
19. p22/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis.
Ropponen KM; Kellokoski JK; Lipponen PK; Pietiläinen T; Eskelinen MJ; Alhava EM; Kosma VM
Br J Cancer; 1999 Sep; 81(1):133-40. PubMed ID: 10487624
[TBL] [Abstract][Full Text] [Related]
20. Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome.
Sup SJ; Alemañy CA; Pohlman B; Elson P; Malhi S; Thakkar S; Steinle R; Hsi ED
J Clin Oncol; 2005 Jun; 23(16):3773-9. PubMed ID: 15809450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
